
    
      Subject who have completed the 24-week Treatment Period of Horizon Protocol HZ-CA-301 or
      HZ-CA-303 without developing an upper gastrointestinal ulcer and who are expected to continue
      to require daily administration of an NSAID for the next 6 months will receive treatment with
      the same study medication received while participating in HZ-CA-301 or HZ-CA-303.
    
  